加速康复外科用于≤2 cm上消化道病变内镜切除:单中心1:2随机对照非劣效性试验
该单中心随机对照非劣效性试验纳入165例≤2 cm上消化道病变行内镜切除(STER、ESD、ESE或EFTR)的患者,按1:2随机分为ERAS组(n=55)和CRAS组(n=110)。主要结局为术后并发症发生率,非劣效界值5%。ERAS组与CRAS组术后并发症风险差为-0.91%(90%CI [-3.97%至3.83%]),符合预设非劣效标准;ERAS组VAS疼痛评分更低、鼻胃管留置时间更短、首次饮水/进食/下床活动时间更早,术后住院时间、总住院时间和住院费用均显著降低(均p<0.001)。
要点
- ERAS用于≤2 cm上消化道病变内镜切除,术后并发症非劣效于常规管理,风险差-0.91%(90%CI -3.97%至3.83%)。
- ERAS组VAS疼痛评分更低(0.0 vs 2.0,p=0.020),鼻胃管留置时间更短(3.0 vs 4.0天,p<0.001)。
- ERAS组首次饮水、进食、下床活动时间更早,术后及总住院时间、住院费用均显著降低(均p<0.001)。
核心结论
- 在入选的≤2 cm上消化道病变患者中,ERAS围术期管理在术后并发症方面达到预设的非劣效标准。
- ERAS还与更短的住院时间和更低的住院费用相关。
研究设计与样本
- 单中心、1:2随机对照非劣效性试验,共纳入165例≤2 cm上消化道病变行内镜切除(STER、ESD、ESE或EFTR)的患者。
- 随机分为ERAS组(n=55)和CRAS组(n=110),主要结局为术后并发症发生率,非劣效界值5%。
主要发现
- ERAS组与CRAS组术后并发症风险差为-0.91%(90%CI [-3.97%至3.83%]),符合预设非劣效标准。
- ERAS组VAS疼痛评分显著更低(0.0 [0.0-3.0] vs 2.0 [0.0-3.3],p=0.020)。
- ERAS组鼻胃管留置时间更短(3.0 [2.0-3.0] vs 4.0 [3.0-4.0]天,p<0.001)。
- ERAS组首次饮水(23.9 [18.5-32.5] vs 64.7 [56.2-77.0]小时)、首次进食(33.2 [22.5-38.5] vs 70.3 [59.2-79.8]小时)、首次下床活动(36.8 [27.0-45.5] vs 76.1 [62.0-86.0]小时)均更早,p<0.001。
- 术后住院时间、总住院时间和住院费用均显著降低(均p<0.001)。
关键数值与推荐
- 非劣效界值设为5%,主要结局为术后并发症发生率。
- ERAS组与CRAS组术后并发症风险差-0.91%(90%CI [-3.97%至3.83%]),达到非劣效。
临床怎么用
- 对于≤2 cm上消化道病变行内镜切除的患者,可考虑采用ERAS围术期管理以缩短住院时间、降低费用并加速康复。
- ERAS方案可包括更早经口饮水/进食、缩短鼻胃管留置和早期下床活动。
局限性
- 单中心研究,样本量有限(ERAS组55例,CRAS组110例)。
- 结论仅适用于经选择的≤2 cm上消化道病变内镜切除患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to preliminarily evaluate the non-inferiority of ERAS-based perioperative management in endoscopic resection for upper gastrointestinal lesions. METHODS: A total of 165 patients with upper gastrointestinal lesions ≤ 2 cm undergoing endoscopic resection (STER, ESD, ESE, or EFTR) were randomized 1:2 to the ERAS group (n = 55) or the conventional recovery after surgery (CRAS) group (n = 110). The primary outcome was postoperative complication rate, with a non-inferiority margin of 5%. Secondary outcomes included postoperative pain, recovery indicators, length of stay, and hospitalization costs. RESULTS: The risk difference in postoperative complications between the ERAS group and the CRAS group was - 0.91% (90% CI [- 3.97% to 3.83%]), meeting the prespecified criterion for non-inferiority. The ERAS group also showed significantly lower VAS pain scores (0.0 [0.0-3.0] vs. 2.0 [0.0-3.3]; p = 0.020), shorter nasogastric tube duration (3.0 [2.0-3.0] vs. 4.0 [3.0-4.0] days; p < 0.001), and earlier time to first oral water (23.9 [18.5-32.5] vs. 64.7 [56.2-77.0] hours; p < 0.001), first oral feeding (33.2 [22.5-38.5] vs. 70.3 [59.2-79.8] hours; p < 0.001), and first ambulation (36.8 [27.0-45.5] vs. 76.1 [62.0-86.0] hours; p < 0.001). Postoperative length of stay, total length of stay, and hospitalization costs were also significantly reduced (all p < 0.001). CONCLUSION: In this single-center trial involving selected patients with upper gastrointestinal lesions ≤ 2 cm, ERAS met the prespecified criterion for non-inferiority to CRAS with respect to postoperative complications. ERAS was also associated with shorter hospital stays and lower hospitalization costs.
引用
- Sun G, Jia W, Liu Z, et al. Enhanced recovery after surgery (ERAS) for endoscopic resection of upper gastrointestinal lesions ≤ 2 cm: a single-center, 1:2 randomized, controlled, non-inferiority trial. Surg Endosc. 2026. PMID: 42897336. doi:10.1007/s00464-026-13383-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。